Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2014; 6(4): 441-447
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.441
Published online Sep 26, 2014. doi: 10.4252/wjsc.v6.i4.441
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?
Christen L Walters Haygood, Rebecca C Arend, J Michael Straughn, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35233, United States
Donald J Buchsbaum, Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, United States
Author contributions: Walters Haygood CL wrote the paper; Arend RC, Straughn JM and Buchsbaum DJ provided critical analysis and manuscript development.
Correspondence to: Christen L Walters Haygood, MD, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 1700 6th Ave South, WIC 10250, Birmingham, AL 35233, United States. cwalters@uabmc.edu
Telephone: +1-205-9345631
Received: June 4, 2014
Revised: July 22, 2014
Accepted: August 30, 2014
Published online: September 26, 2014
Processing time: 113 Days and 10.8 Hours
Revised: July 22, 2014
Accepted: August 30, 2014
Published online: September 26, 2014
Processing time: 113 Days and 10.8 Hours
Core Tip
Core tip: Ovarian cancer stem cells (CSCs) are difficult to isolate, identify, and target. However, they are often thought to be the source of development of chemoresistance. Finding a therapeutic target in ovarian CSCs and identifying the mechanisms associated with the development of chemoresistance may lead to a long-lasting cure for patients with epithelial ovarian cancer.